Trials Offered by a Specific Doctor

Elizabeth Verna, MD

Dr. Elizabeth C. Verna manages patients with a variety of liver diseases. Her clinical interests focus on viral hepatitis and liver transplantation as well as the new emerging therapies for hepatitis C, liver cancer, alcoholic and non-alcoholic fatty liver disease and metabolic liver diseases. She also has expertise in the management of end stage liver disease and its complications.

Clinical Studies Managed By Dr. Verna:
More InfoTitleSponsorIRB Number
Details[CLOSED] Study for liver transplant recipients using drug (IgG) to prevent Hepatitis C virus (HCV) recurrenceBiotest Pharmaceuticals CorporationAAAL8001
Details[CLOSED] Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD) using trial drugsMerck & Co. IncAAAL5200
Details[CLOSED] A study for liver transplant patients with Chronic HCV using study drug HarvoniGilead SciencesAAAO4208
Details[CLOSED] A study for patients with Chronic HCV Infection using study drugs Sofosbuvir, Velpatasvir and GS-9857GileadAAAQ4250
Details[CLOSED] A study for patients with Chronic HCV Infection using study drug combination Sofosbuvir/Velpatasvir/GS-9857GileadAAAQ4053
Details[CLOSED] A study for patients with Chronic Genotype 3 HCV Infection and Cirrhosis using study drugs Sofosbuvir, Velpatasvir and GS-9857Gilead Sciences, IncAAAQ4900
Details[CLOSED] A study for patients with Non-Alcoholic Steatohepatitis (NASH using study drug armacholGalmedAAAQ3206
Details[CLOSED] A study for patients with Chronic HCV Infection who have not received an NS5A Inhibitor using study drugs Sofosbuvir/Velpatasvir/GS-9857Gilead Sciences, IncAAAQ4901
DetailsA study for patients with chronic hepatitis C and advanced heart failure or lung disease using study drug HarvoniGilead Sciences, IncAAAR0896
Details[CLOSED] Study of Emricasan in subjects with Non-Alcoholic Steatohepatitis (NASH) CirrhosisConatus Pharmaceuticals, Inc.AAAR5409
DetailsGLIMMER: Study of Drug in Treatment of Pruritus (Itching) in Patients with Primary Biliary CholangitisGlaxoSmithKlineAAAR2207
DetailsA 5-Year Study of the Natural History and Management of Patients with Hepatocellular Carcioma (A Type of Liver Cancer)TARGET PharmaSolutions, Inc.AAAR3667
Details[CLOSED] TARGET-NASH: Longitudinal Observational Study of Patients with Nonalcoholic Fatty Liver or Nonalcoholic SteatohepatitisTARGET PharmaSolutions, Inc.AAAR3890
Details[CLOSED] THE PRIORITIZE STUDY: Study of Oral Regimens for Hepatitis CUniversity of FloridaAAAQ8487
DetailsAn observational study of patients undergoing therapy for Chronic Hepatitis B (HBV) InfectionTarget PharmaSolutions, IncAAAS1162
DetailsStudy of seladelpar in subjects with primary biliary cholangitis (PBC)CymaBay Therapeutics, Inc.AAAS1003
DetailsRegistry Study of Adult Patients with Primary Sclerosing Cholangitis (PSC)InternalAAAR9400
DetailsPrevention of Hepatitis C with Antiviral HCV Therapy After Liver and/or Kidney TransplantUniversity of California, San FranciscoAAAR8005